OncoMatch/Clinical Trials/NCT07200544
Meloxicam in Mohs Micrographic Surgery
Is NCT07200544 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Meloxicam 7.5 mg and Meloxicam 15 mg for postoperative pain, acute.
Treatment: Meloxicam 7.5 mg · Meloxicam 15 mg · Acetaminophen 500mg — The goal of this clinical trial is to explore alternative methods of postoperative pain control in Mohs micrographic surgery. The main aims are: * To provide more information to the Mohs surgery community regarding postoperative pain control. * Reducing pain improves the overall comfort and well-being of patients, leading to a better post-operative experience. * To provide patients with an alternative and potentially superior NSAID for pain control (compared to standard-of-care ibuprofen). Researchers will compare 1) a single of dose Meloxicam 7.5 mg, followed by acetaminophen 500 mg; 2) a single dose of Meloxicam 15 mg, followed by acetaminophen 500 mg; 3) a single dose of acetaminophen 500 mg, followed by alternating ibuprofen 200 mg and acetaminophen 500 mg to see which better moderate pain control and patient satisfaction. Participants will be asked to complete pain and patient satisfaction surveys.
Check if I qualifyEligibility summary
For patients with skin cancer.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
US trial sites
- University of Oklahoma Health Sciences Center · Oklahoma City, Oklahoma
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify